Rudiger Waldherr
Overview
Explore the profile of Rudiger Waldherr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
1889
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fichtner A, Gauche L, Susal C, Tran T, Waldherr R, Krupka K, et al.
Pediatr Nephrol
. 2024 Sep;
40(2):491-503.
PMID: 39283519
Background: This study by the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN) was designed to determine the incidence, risk factors, current management strategies, and outcomes of antibody-mediated rejection (ABMR) in...
2.
Benning L, Morath C, Fink A, Rudek M, Speer C, Kalble F, et al.
Transpl Int
. 2023 Nov;
36:11899.
PMID: 38020751
Donor-derived cell-free DNA (dd-cfDNA) identifies allograft injury and discriminates active rejection from no rejection. In this prospective study, 106 kidney transplant recipients with 108 clinically indicated biopsies were enrolled at...
3.
Schaier M, Morath C, Wang L, Kleist C, Opelz G, Tran T, et al.
Front Immunol
. 2023 Jul;
14:1089664.
PMID: 37483623
Background: The administration of modified immune cells (MIC) before kidney transplantation led to specific immunosuppression against the allogeneic donor and a significant increase in regulatory B lymphocytes. We wondered how...
4.
Feurstein S, Zoller J, Schwab C, Schreiner S, Mundt H, Breitkreutz I, et al.
EJHaem
. 2022 Dec;
3(4):1377-1380.
PMID: 36467828
Due to differences in the protein folding mechanisms, it is exceedingly rare for amyloid light chain (AL) amyloidosis and monoclonal gammopathy of renal significance (MGRS) to coexist. We herein report...
5.
Schnuelle P, Schwab C, Waldherr R, Zeier M, Bischofs C
J Nephrol
. 2022 Nov;
36(3):631-633.
PMID: 36409427
No abstract available.
6.
Morath C, Schmitt A, Schmitt M, Wang L, Kleist C, Opelz G, et al.
BMJ Open
. 2022 Nov;
12(11):e066128.
PMID: 36368749
Introduction: Donor-derived modified immune cells (MIC) induced long-term specific immunosuppression against the allogeneic donor in preclinical models of transplantation. In a phase I clinical trial (TOL-1 Study), MIC treatment resulted...
7.
Morath C, Schaier M, Ibrahim E, Wang L, Kleist C, Opelz G, et al.
J Am Soc Nephrol
. 2022 Sep;
34(1):160-174.
PMID: 36137752
Background: We recently demonstrated that donor-derived modified immune cells (MICs)-PBMCs that acquire immunosuppressive properties after a brief treatment-induced specific immunosuppression against the allogeneic donor when administered before kidney transplantation. We...
8.
Fichtner A, Susal C, Hocker B, Rieger S, Waldherr R, Westhoff J, et al.
Pediatr Nephrol
. 2021 Mar;
36(8):2473-2484.
PMID: 33759004
Background: Non-HLA antibodies against endothelial targets have been implicated in the pathogenesis of antibody-mediated rejection (ABMR), but data in pediatric patients are scarce. Methods: We retrospectively analyzed a carefully phenotyped...
9.
Morath C, Schmitt A, Kleist C, Daniel V, Opelz G, Susal C, et al.
J Clin Invest
. 2020 Jan;
130(5):2364-2376.
PMID: 31990685
BACKGROUNDPreclinical experiments have shown that donor blood cells, modified in vitro by an alkylating agent (modified immune cells [MICs]), induced long-term specific immunosuppression against the allogeneic donor.METHODSIn this phase I...
10.
Speer C, Kalble F, Nusshag C, Pego da Silva L, Schaier M, Becker L, et al.
Transpl Int
. 2019 Jul;
32(12):1286-1296.
PMID: 31322786
Because of the current organ shortage, ABO-incompatible (ABOi) transplantations have been increasingly performed in recent years. The results seem comparable to those of compatible transplantations, but there have also been...